Evidence map›Paper›PMID 38549684›Full record

ArticleJournal of pharmaceutical policy and practice2024

The cost associated with the development of the antimicrobial stewardship program in the adult general medicine setting in Qatar.

Dina Abushanab, Wafa Al-Marridi, Moza Al Hail, Palli Valappila Abdul Rouf, Wessam ElKassem, Binny Thomas, Hussam Alsoub, Zanfina Ademi, Yolande Hanssens, Rasha El Enany and 1 more

Abstract read
In one paragraph

Article in Journal of pharmaceutical policy and practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dina AbushanabDepartment of Pharmacy, Hamad Medical Corporation, Doha, Qatar.ORCID https://orcid.org/0000-0002-4162-8617
Wafa Al-MarridiCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Moza Al HailDepartment of Pharmacy, Hamad Medical Corporation, Doha, Qatar.ORCID https://orcid.org/0000-0003-4991-982X
Palli Valappila Abdul RoufDepartment of Pharmacy, Hamad Medical Corporation, Doha, Qatar.ORCID https://orcid.org/0000-0002-6924-8245
Wessam ElKassemDepartment of Pharmacy, Hamad Medical Corporation, Doha, Qatar.ORCID https://orcid.org/0000-0003-2145-7555
Binny ThomasDepartment of Pharmacy, Hamad Medical Corporation, Doha, Qatar.ORCID https://orcid.org/0000-0003-1065-8343
Hussam AlsoubDepartment of Medicine, Hamad Medical Corporation, Doha, Qatar.
Zanfina AdemiCentre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.
Yolande HanssensDepartment of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
Rasha El EnanyDepartment of Pharmacy, Hamad Medical Corporation, Doha, Qatar.ORCID https://orcid.org/0000-0002-4092-5118
Daoud Al-BadriyehCollege of Pharmacy, QU Health, Qatar University, Doha, Qatar.ORCID https://orcid.org/0000-0001-7791-954X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To estimate the economic impact of the developed antimicrobial stewardship program (ASP) versus the preliminary ASP use, in the adults' general medicine settings in Qatar. Methods: Patient records were retrospectively reviewed during two periods: preliminary ASP was defined as the 12 months following ASP implementation (i.e. May 2015-April 2016), and developed ASP was defined as the last 12 months of a 5-year ASP implementation in Hamad Medical Corporation (HMC) (i.e. February 2019-January 2020). The economic impact was the overall cost savings in resource use, including operational costs, plus the cost avoidance associated with ASP. Results: A total of 500 patients were included in the study. The operational costs decreased with the developed ASP. Whereas antimicrobial consumption and resource utilisation, and their associated costs, appear to have declined with the developed ASP, with a cost saving of QAR458 (US$125) per 100-patient beds, the avoided cost was negative, by QAR4,807 (US$1,317) per 100-patient beds, adding to a total QAR4,224 (US$1,160) increase in the 100-patient beds cost after ASP development. Conclusions: Despite that the developed ASP attained a total cost saving QAR458 (US$125) per 100-patient beds, the avoided cost was QAR-4,807 (US$-1,317) per 100-patient beds, which exceeded the cost savings achieved.

Indexed as

AntimicrobialCostEconomic impactGeneral medicineServiceStewardship

Identifiers

PMID38549684
PMCPMC10977017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.